TRICHODIENE


Molecule Category	Free-form
UNII	697ERP55B1
Source	Gaulton A, Kale N, van Westen GJ, Bellis LJ, Bento AP, Davies M, Hersey A, Papadatos G, Forster M, Wege P, Overington JP. A large-scale crop protection bioassay data set. Sci Data. 2015 Jul 7;2:150032. Read more ...


Active Pharmaceutical Ingredients Bioactive chemicals	Exact Similarity SubStructure	Threshold (%) >= 70

Structure


InChI Key	YFLSTROSSKYYNK-CABCVRRESA-N
Smiles	CC1=CC[C@](C)(CC1)[C@@]2(C)CCCC2=C
InChI	InChI=1S/C15H24/c1-12-7-10-14(3,11-8-12)15(4)9-5-6-13(15)2/h7H,2,5-6,8-11H2,1,3-4H3/t14-,15+/m1/s1

Physicochemical Descriptors

Property Name	Value
Molecular Formula	C15H24
Molecular Weight	204.35
AlogP	4.71
Hydrogen Bond Acceptor	0.0
Hydrogen Bond Donor	0.0
Number of Rotational Bond	1.0
Polar Surface Area	0.0
Molecular species	None
Aromatic Rings	0.0
Heavy Atoms	15.0

Assay Description	Organism	Bioactivity
Phytotoxicity against Arabidopsis thaliana Col-4 leaves assessed as induction of leaf death at 100 uM after 7 weeks post compound application by detached leaf assay	Arabidopsis thaliana	3.0 %
Phytotoxicity against Arabidopsis thaliana Col-4 leaves assessed as induction of chlorosis at 100 uM after 7 weeks post compound application by detached leaf assay	Arabidopsis thaliana	10.0 %
Phytotoxicity against Arabidopsis thaliana Col-4 leaves assessed as induction of chlorosis, shriveling or death of leaves after 7 weeks post compound application by detached leaf assay	Arabidopsis thaliana	100.0 uM

Cross References

Resources	Reference
ChEMBL	CHEMBL2251626
FDA SRS	697ERP55B1
PubChem	114857
SureChEMBL	SCHEMBL717002

CONTENTS


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).